Literature DB >> 31855300

Epistasis between phenylethanolamine N-methyltransferase and β2-adrenergic receptor influences extracellular epinephrine level and associates with the susceptibility to allergic asthma.

Yang Yie Sio1, Sri Anusha Matta1, Yu Ting Ng1, Fook Tim Chew1.   

Abstract

BACKGROUND: Reduced extracellular epinephrine level often associates with asthma-related symptoms; however, the correlation between asthma and genetic variants in genes participating in the epinephrine signalling pathway remains unclear.
OBJECTIVE: To characterize the functions of single nucleotide polymorphisms (SNPs) in phenylethanolamine N-methyltransferase (PNMT) and β2-adrenergic receptor (ADRB2), and to study the effects, including both direct and epistatic, of these SNPs on serum epinephrine level and asthma susceptibility.
METHODS: Single nucleotide polymorphisms functions were characterized through in vitro luciferase assay. ADRB2 gene expression level in peripheral blood mononuclear cell (PBMC) was measured by transcriptome sequencing and expression microarray on two separate Asian cohorts (NUS-UTAR, n = 278 and NUS-TA, n = 58). Serum epinephrine level was assessed on a Singapore Chinese cohort (NUS-SH, n = 314) with 155 asthmatic and 159 non-asthmatic subjects. A separate Singapore Chinese cohort (NUS-G, n = 3009) was genotyped to show disease association (direct and epistatic effect) of functional SNPs in PNMT and ADRB2.
RESULTS: Reduced serum epinephrine level was associated with increased asthma risk in Singapore Chinese. The minor allele of rs876493 was shown to increase PNMT promoter activity and reduce asthma risk. Multiple SNPs in ADRB2 forms a haplotype that was associated with the differential promoter activity of this gene. In this haplotype, rs11168070 was associated directly with ADRB2 expression in PBMCs. Both minor alleles from rs876493 and rs11168070 contribute synergistically to reduce asthma risk and increase serum epinephrine level. CONCLUSION AND CLINICAL RELEVANCE: Epistatic interaction between genetic variants from PNMT (rs876493) and ADRB2 (rs11168070) is associated with serum epinephrine level and the susceptibility of asthma. Our findings improved the current understanding of the genetic basis of this disease, while genotypic states of these SNPs may serve as potential biomarkers to predict susceptibility to the disease.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  asthma; basic mechanisms; genetics

Mesh:

Substances:

Year:  2020        PMID: 31855300     DOI: 10.1111/cea.13552

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  5 in total

1.  Association between ADRB2 regulatory region polymorphisms and susceptibility to childhood asthma.

Authors:  Ming-Xuan Cai; Bing Wei; Shi-E Liao; Jin-Yue Fu; Ya-Jun Liu; Ling-Xue Li
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2021-11-15

Review 2.  Insights into S-adenosyl-l-methionine (SAM)-dependent methyltransferase related diseases and genetic polymorphisms.

Authors:  Jiaojiao Li; Chunxiao Sun; Wenwen Cai; Jing Li; Barry P Rosen; Jian Chen
Journal:  Mutat Res Rev Mutat Res       Date:  2021-10-07       Impact factor: 7.015

3.  Spatiotemporal Changes in the Gene Expression Spectrum of the β2 Adrenergic Receptor Signaling Pathway in the Lungs of Rhesus Monkeys.

Authors:  Zhongmei Zheng; Bangrong Cao; Yu Hu; Liang Xie; Ling Gu; Fang Shi; Hanmin Liu
Journal:  Lung       Date:  2021-01-29       Impact factor: 2.584

4.  The landscape of GWAS validation; systematic review identifying 309 validated non-coding variants across 130 human diseases.

Authors:  Ammar J Alsheikh; Sabrina Wollenhaupt; Emily A King; Jonas Reeb; Sujana Ghosh; Lindsay R Stolzenburg; Saleh Tamim; Jozef Lazar; J Wade Davis; Howard J Jacob
Journal:  BMC Med Genomics       Date:  2022-04-01       Impact factor: 3.063

Review 5.  Potential cellular endocrinology mechanisms underlying the effects of Chinese herbal medicine therapy on asthma.

Authors:  Zeyu Meng; Huize Chen; Chujun Deng; Shengxi Meng
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-16       Impact factor: 6.055

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.